A multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Trial Profile

A multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ADHERE; CHARM
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Nov 2016 Results of post hoc analysis of this and other five studies (CLASSIC-I, GAIN, CHARM, EXTEND, ULTRA 1 AND ULTRA 2) published in the Alimentary Pharmacology and Therapeutics
    • 27 Sep 2016 Results of pooled analysis from this and other nine trials (CLASSIC I and II, GAIN, CHARM, EXTEND, CARE, ACCESS, ADHERE) assessing the risk of serious and opportunistic infections in patients with treated with adalimumab (n=2266) published in the American Journal of Gastroenterology.
    • 19 May 2012 Sub-group results presented at the Digestive Disease Week 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top